ARCTURUS THERAPEUTICS HOLDINGS INC. Comprehensive Income
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Comprehensive Income of -$23.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$23.79M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$26.96M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$29.08M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$13.45M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$65.78M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$80.94M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$29.73M, a 417.95% decline from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was $9.35M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$23.79M 10-Q · filed 2026-08-06 | -$50.75M 10-Q · filed 2026-08-06 | -$79.83M derived: sum of 3 quarters · filed 2026-08-06 | -$93.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$26.96M 10-Q · filed 2026-05-07 | -$56.04M derived: sum of 2 quarters · filed 2026-05-07 | -$69.49M derived: sum of 3 quarters · filed 2026-05-07 | -$78.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$29.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$42.53M derived: sum of 2 quarters · filed 2026-03-03 | -$51.71M derived: sum of 3 quarters · filed 2026-08-06 | -$65.78M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$13.45M 10-Q · filed 2025-11-12 | -$22.63M derived: sum of 2 quarters · filed 2026-08-06 | -$36.70M 10-Q · filed 2025-11-12 | -$66.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$9.18M 10-Q · filed 2026-08-06 | -$23.26M 10-Q · filed 2026-08-06 | -$53.26M derived: sum of 3 quarters · filed 2026-08-06 | -$60.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$14.08M 10-Q · filed 2026-05-07 | -$44.08M derived: sum of 2 quarters · filed 2026-05-07 | -$50.98M derived: sum of 3 quarters · filed 2026-05-07 | -$68.20M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$36.91M derived: sum of 2 quarters · filed 2026-03-03 | -$54.12M derived: sum of 3 quarters · filed 2026-03-03 | -$80.94M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$6.90M 10-Q · filed 2025-11-12 | -$24.12M derived: sum of 2 quarters · filed 2025-11-12 | -$50.94M 10-Q · filed 2025-11-12 | -$62.64M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | -$17.22M 10-Q · filed 2025-08-11 | -$44.03M 10-Q · filed 2025-08-11 | -$55.74M derived: sum of 3 quarters · filed 2026-03-03 | -$71.96M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$26.82M 10-Q · filed 2025-05-12 | -$38.52M derived: sum of 2 quarters · filed 2026-03-03 | -$54.75M derived: sum of 3 quarters · filed 2026-03-03 | -$107.30M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$11.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$27.93M derived: sum of 2 quarters · filed 2026-03-03 | -$80.48M derived: sum of 3 quarters · filed 2026-03-03 | -$29.73M 10-K · filed 2026-03-03 |
| 2023-09-30 | -$16.22M 10-Q · filed 2024-11-07 | -$68.77M derived: sum of 2 quarters · filed 2024-11-07 | -$18.02M 10-Q · filed 2024-11-07 | $99.33M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$52.55M 10-Q · filed 2024-08-05 | -$1.80M 10-Q · filed 2024-08-05 | $115.55M derived: sum of 3 quarters · filed 2025-03-06 | $80.28M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $50.75M 10-Q · filed 2024-05-08 | $168.10M derived: sum of 2 quarters · filed 2025-03-06 | $132.84M derived: sum of 3 quarters · filed 2025-03-06 | $111.27M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $117.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $82.08M derived: sum of 2 quarters · filed 2025-03-06 | $60.52M derived: sum of 3 quarters · filed 2025-03-06 | $9.35M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$35.27M 10-Q · filed 2023-11-14 | -$56.83M derived: sum of 2 quarters · filed 2023-11-14 | -$108.00M 10-Q · filed 2023-11-14 | -$146.66M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | -$21.56M 10-Q · filed 2023-08-07 | -$72.73M 10-Q · filed 2023-08-07 | -$111.39M derived: sum of 3 quarters · filed 2024-03-14 | -$165.48M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | -$51.17M 10-Q · filed 2023-05-09 | -$89.83M derived: sum of 2 quarters · filed 2024-03-14 | -$143.92M derived: sum of 3 quarters · filed 2024-03-14 | -$198.50M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | -$38.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$92.75M derived: sum of 2 quarters · filed 2024-03-14 | -$147.33M derived: sum of 3 quarters · filed 2024-03-14 | -$203.67M 10-K · filed 2024-03-14 |
| 2021-09-30 | -$54.08M 10-Q · filed 2022-11-09 | -$108.67M derived: sum of 2 quarters · filed 2022-11-09 | -$165.01M 10-Q · filed 2022-11-09 | -$196.12M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$54.58M 10-Q · filed 2022-08-09 | -$110.93M 10-Q · filed 2022-08-09 | -$142.03M derived: sum of 3 quarters · filed 2022-08-09 | -$163.03M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$56.35M 10-Q · filed 2022-05-09 | -$87.45M derived: sum of 2 quarters · filed 2022-05-09 | -$108.45M derived: sum of 3 quarters · filed 2022-05-09 | -$118.72M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$31.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$52.11M derived: sum of 2 quarters · filed 2022-03-01 | -$62.37M derived: sum of 3 quarters · filed 2022-03-01 | -$72.15M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$21.00M 10-Q · filed 2021-11-09 | -$31.27M derived: sum of 2 quarters · filed 2021-11-09 | -$41.04M 10-Q · filed 2021-11-09 | -$52.03M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$10.26M 10-Q · filed 2021-08-10 | -$20.04M 10-Q · filed 2021-08-10 | -$31.03M derived: sum of 3 quarters · filed 2022-03-01 | -$38.46M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$9.78M 10-Q · filed 2021-05-10 | -$20.77M derived: sum of 2 quarters · filed 2022-03-01 | -$28.20M derived: sum of 3 quarters · filed 2022-03-01 | -$28.88M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$10.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$18.42M derived: sum of 2 quarters · filed 2022-03-01 | -$19.11M derived: sum of 3 quarters · filed 2022-03-01 | -$25.99M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$7.43M 10-Q · filed 2020-11-09 | -$8.12M derived: sum of 2 quarters · filed 2020-11-09 | -$15.00M 10-Q · filed 2020-11-09 | -$16.02M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$685.00K 10-Q · filed 2020-08-10 | -$7.57M 10-Q · filed 2020-08-10 | -$8.58M derived: sum of 3 quarters · filed 2021-03-01 | -$12.84M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$6.88M 10-Q · filed 2020-05-08 | -$7.90M derived: sum of 2 quarters · filed 2021-03-01 | -$12.15M derived: sum of 3 quarters · filed 2021-03-01 | -$22.09M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$5.27M derived: sum of 2 quarters · filed 2021-03-01 | -$15.21M derived: sum of 3 quarters · filed 2021-03-01 | -$21.78M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$4.25M 10-Q · filed 2019-11-08 | -$14.19M derived: sum of 2 quarters · filed 2019-11-08 | -$20.77M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | -$9.94M 10-Q · filed 2019-08-14 | -$16.52M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |